BoironLTS:0DTF 73 EBITDA Margin % is 13.10% as of Dec. 2025, which is 22% below its 10-year median of 16.71. GuruFocus rates LTS:0DTF with a GF Score™ of 73/100 and a GF Value™ of €33.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Boiron ranks better than 50.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Boiron's EBITDA for the
six
months ended in Dec. 2025 was €33.5 Mil. Boiron's Revenue for the
six
months ended in Dec. 2025 was €255.5 Mil. Therefore, Boiron's EBITDA margin for the quarter that ended in Dec. 2025 was 13.10%.
Boiron (LTS:0DTF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Boiron EBITDA Margin % Related Terms
Boiron EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Boiron's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DTF vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Boiron's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (LTS:0DTF) has a EBITDA Margin % of 13.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boiron and its competitors. This is 22% below median its historical median of 16.71. Over the past decade, Boiron's EBITDA Margin % has ranged from 11.93 to 25.55. According to the industry distribution chart, Boiron ranks #476 out of 955 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is Boiron's EBITDA Margin % too high?
Boiron's current EBITDA Margin % of 13.10% is 22% below median its 10-year median of 16.71. Over the past 10 years, this metric has ranged from a low of 11.93 to a high of 25.55. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Boiron's value of 13.10% is 5.3% above this industry median. Based on the distribution chart, Boiron ranks #476 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Boiron has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boiron's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #476 out of 955 companies for EBITDA Margin %. This puts Boiron in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Boiron's value of 13.10% is 5.3% above this benchmark. Historically, Boiron's own EBITDA Margin % has ranged from 11.93 to 25.55 over the past decade. While the company's 10-year median is 16.71 vs. the industry median of 12.44, Boiron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current EBITDA Margin % of 13.10% is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current EBITDA Margin % is 13.10%, which is 22% below median its own 10-year median of 16.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (LTS:0DTF) is currently considered Modestly Undervalued. The stock's GF Value™ is €33.63, compared to a current price of €27.70 — trading 17.6% below its estimated fair value. The current EBITDA Margin % is 13.10%, which is 22% below median its 10-year median of 16.71 and 5.3% above the Drug Manufacturers industry median of 12.44. Boiron's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Boiron (LTS:0DTF), the current EBITDA Margin % is 13.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (LTS:0DTF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of €27.70 is trading 17.6% below its estimated GF Value™ of €33.63.
GuruFocus considers Boiron to be Modestly Undervalued.
Key valuation signals for LTS:0DTF:
EBITDA Margin %: 13.10% (22% below median its 10-year median of 16.71)
GF Value™: €33.63 vs. price of €27.70 (17.6% below fair value)
Industry Position: 5.3% above the Drug Manufacturers median (#476 of 955)
No single metric tells the full story. See the LTS:0DTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
73GF Score
Get the complete analysis for LTS:0DTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DTF has been successfully added to your 
